|Awarded On||March 29, 2012|
|Title||Development and Pre-clinical Testing of Therapeutic MYCN Vaccine|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Leonid S Metelitsa|
The overall goal of project-3 is to develop a safe and effective immunotherapy of neuroblastoma (NB) by targeting MYCN oncogene with a novel type of cancer vaccine. MYCN is a causative oncogene in MYCN-amplified (MYCN-A) NB, the most deadly type of the disease. MYCN represents a nearly ideal target for immunotherapy since it is highly expressed in the malignant neuroblasts, essential for their survival, and not detectable in normal tissues after birth. We recently reported a new type of oral cancer vaccine that uses type-3 secretion system of Salmonella to translocate tumor-associated antigens into the cytosol of antigen-presenting cells. Our new MYCN vaccine carried by an attenuated Salmone...